AIM Vaccine Co. Ltd. announced that it has received approval from the National Medical Products Administration to commence clinical trials for its 20-valent pneumococcal polysaccharide conjugate vaccine. The approval allows the company to begin clinical studies of this optimized and upgraded vaccine, which builds upon its earlier 13-valent pneumococcal conjugate vaccine. Currently, only Pfizer's Prevenar 20 is approved for marketing abroad, and no comparable vaccine has received marketing approval in China. AIM Vaccine Co. Ltd. stated that this approval marks an expansion of its R&D pipeline in the pneumococcal vaccine field.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM Vaccine Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260119-11994998), on January 19, 2026, and is solely responsible for the information contained therein.